JP7216007B2 - 硬化した生分解性微粒子及び足場材料、並びにそれらの製造方法及び使用方法 - Google Patents
硬化した生分解性微粒子及び足場材料、並びにそれらの製造方法及び使用方法 Download PDFInfo
- Publication number
- JP7216007B2 JP7216007B2 JP2019553806A JP2019553806A JP7216007B2 JP 7216007 B2 JP7216007 B2 JP 7216007B2 JP 2019553806 A JP2019553806 A JP 2019553806A JP 2019553806 A JP2019553806 A JP 2019553806A JP 7216007 B2 JP7216007 B2 JP 7216007B2
- Authority
- JP
- Japan
- Prior art keywords
- pgs
- microparticles
- phase
- poly
- particulates
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000011859 microparticle Substances 0.000 title claims description 199
- 238000000034 method Methods 0.000 title claims description 123
- 239000000463 material Substances 0.000 title claims description 66
- 239000002245 particle Substances 0.000 claims description 92
- 239000000203 mixture Substances 0.000 claims description 85
- 229920005989 resin Polymers 0.000 claims description 62
- 239000011347 resin Substances 0.000 claims description 62
- 239000007788 liquid Substances 0.000 claims description 56
- 229920000615 alginic acid Polymers 0.000 claims description 51
- 229940072056 alginate Drugs 0.000 claims description 50
- -1 poly(glycerol sebacate) Polymers 0.000 claims description 50
- 235000010443 alginic acid Nutrition 0.000 claims description 37
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 36
- 239000003814 drug Substances 0.000 claims description 31
- 229940079593 drug Drugs 0.000 claims description 30
- 238000013270 controlled release Methods 0.000 claims description 29
- 238000002156 mixing Methods 0.000 claims description 29
- 229920001971 elastomer Polymers 0.000 claims description 26
- 239000000806 elastomer Substances 0.000 claims description 26
- 229920001187 thermosetting polymer Polymers 0.000 claims description 26
- 239000011148 porous material Substances 0.000 claims description 21
- 239000011159 matrix material Substances 0.000 claims description 20
- 239000000945 filler Substances 0.000 claims description 19
- 230000008569 process Effects 0.000 claims description 18
- 239000000243 solution Substances 0.000 claims description 16
- 238000010438 heat treatment Methods 0.000 claims description 15
- 239000000839 emulsion Substances 0.000 claims description 12
- 230000004936 stimulating effect Effects 0.000 claims description 9
- 238000011068 loading method Methods 0.000 claims description 6
- 230000005855 radiation Effects 0.000 claims description 6
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 5
- VQTUBCCKSQIDNK-UHFFFAOYSA-N Isobutene Chemical group CC(C)=C VQTUBCCKSQIDNK-UHFFFAOYSA-N 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 239000003431 cross linking reagent Substances 0.000 claims description 3
- 239000004820 Pressure-sensitive adhesive Substances 0.000 description 53
- 239000000843 powder Substances 0.000 description 46
- 239000004005 microsphere Substances 0.000 description 36
- 239000003795 chemical substances by application Substances 0.000 description 30
- 150000002148 esters Chemical class 0.000 description 24
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 21
- 230000015572 biosynthetic process Effects 0.000 description 20
- 229920000642 polymer Polymers 0.000 description 19
- 238000001723 curing Methods 0.000 description 17
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical compound OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 description 16
- 206010052428 Wound Diseases 0.000 description 15
- 208000027418 Wounds and injury Diseases 0.000 description 15
- 229920001577 copolymer Polymers 0.000 description 14
- 239000000654 additive Substances 0.000 description 12
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 12
- 239000008186 active pharmaceutical agent Substances 0.000 description 11
- 238000000137 annealing Methods 0.000 description 11
- 238000009472 formulation Methods 0.000 description 11
- 239000002480 mineral oil Substances 0.000 description 11
- 235000010446 mineral oil Nutrition 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 238000013019 agitation Methods 0.000 description 10
- 239000002775 capsule Substances 0.000 description 10
- 206010028980 Neoplasm Diseases 0.000 description 9
- 239000002253 acid Substances 0.000 description 9
- 239000000499 gel Substances 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- 229920002367 Polyisobutene Polymers 0.000 description 8
- 238000004132 cross linking Methods 0.000 description 8
- 238000004945 emulsification Methods 0.000 description 8
- 239000005076 polymer ester Substances 0.000 description 8
- 238000007634 remodeling Methods 0.000 description 8
- 239000000758 substrate Substances 0.000 description 8
- 230000007704 transition Effects 0.000 description 8
- 206010020843 Hyperthermia Diseases 0.000 description 7
- 239000000853 adhesive Substances 0.000 description 7
- 230000001070 adhesive effect Effects 0.000 description 7
- 239000003242 anti bacterial agent Substances 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 7
- 239000003995 emulsifying agent Substances 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 230000036031 hyperthermia Effects 0.000 description 7
- 238000005245 sintering Methods 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 229940109262 curcumin Drugs 0.000 description 6
- 235000012754 curcumin Nutrition 0.000 description 6
- 239000004148 curcumin Substances 0.000 description 6
- 239000008367 deionised water Substances 0.000 description 6
- 229910021641 deionized water Inorganic materials 0.000 description 6
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 239000002105 nanoparticle Substances 0.000 description 6
- 235000016709 nutrition Nutrition 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 6
- 239000003381 stabilizer Substances 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 230000000996 additive effect Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 239000011258 core-shell material Substances 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- 239000007789 gas Substances 0.000 description 5
- 230000005484 gravity Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 229920001169 thermoplastic Polymers 0.000 description 5
- 239000004416 thermosoftening plastic Substances 0.000 description 5
- 239000004372 Polyvinyl alcohol Substances 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 239000002019 doping agent Substances 0.000 description 4
- 230000005670 electromagnetic radiation Effects 0.000 description 4
- 238000011065 in-situ storage Methods 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 239000000178 monomer Substances 0.000 description 4
- 239000002952 polymeric resin Substances 0.000 description 4
- 229920002451 polyvinyl alcohol Polymers 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 229920003002 synthetic resin Polymers 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 240000003553 Leptospermum scoparium Species 0.000 description 3
- 235000016887 Leptospermum scoparium Nutrition 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 229940030225 antihemorrhagics Drugs 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 239000012867 bioactive agent Substances 0.000 description 3
- 239000003124 biologic agent Substances 0.000 description 3
- 150000001768 cations Chemical class 0.000 description 3
- 239000000919 ceramic Substances 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 239000002781 deodorant agent Substances 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 238000012377 drug delivery Methods 0.000 description 3
- 230000003628 erosive effect Effects 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 239000010419 fine particle Substances 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000007952 growth promoter Substances 0.000 description 3
- 239000002874 hemostatic agent Substances 0.000 description 3
- 235000012907 honey Nutrition 0.000 description 3
- 239000000017 hydrogel Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000009768 microwave sintering Methods 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- ARIWANIATODDMH-UHFFFAOYSA-N rac-1-monolauroylglycerol Chemical compound CCCCCCCCCCCC(=O)OCC(O)CO ARIWANIATODDMH-UHFFFAOYSA-N 0.000 description 3
- 239000008279 sol Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- FTEDXVNDVHYDQW-UHFFFAOYSA-N BAPTA Chemical compound OC(=O)CN(CC(O)=O)C1=CC=CC=C1OCCOC1=CC=CC=C1N(CC(O)=O)CC(O)=O FTEDXVNDVHYDQW-UHFFFAOYSA-N 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 229910021580 Cobalt(II) chloride Inorganic materials 0.000 description 2
- 239000004971 Cross linker Substances 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 238000001157 Fourier transform infrared spectrum Methods 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 238000005054 agglomeration Methods 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- WDIHJSXYQDMJHN-UHFFFAOYSA-L barium chloride Chemical compound [Cl-].[Cl-].[Ba+2] WDIHJSXYQDMJHN-UHFFFAOYSA-L 0.000 description 2
- 229910001626 barium chloride Inorganic materials 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000021164 cell adhesion Effects 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 238000002659 cell therapy Methods 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000013522 chelant Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 229950007919 egtazic acid Drugs 0.000 description 2
- 238000010336 energy treatment Methods 0.000 description 2
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 229940097789 heavy mineral oil Drugs 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 238000011415 microwave curing Methods 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- WLJVNTCWHIRURA-UHFFFAOYSA-N pimelic acid Chemical compound OC(=O)CCCCCC(O)=O WLJVNTCWHIRURA-UHFFFAOYSA-N 0.000 description 2
- 229920001610 polycaprolactone Polymers 0.000 description 2
- 239000004632 polycaprolactone Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000011342 resin composition Substances 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 229910001631 strontium chloride Inorganic materials 0.000 description 2
- AHBGXTDRMVNFER-UHFFFAOYSA-L strontium dichloride Chemical compound [Cl-].[Cl-].[Sr+2] AHBGXTDRMVNFER-UHFFFAOYSA-L 0.000 description 2
- TYFQFVWCELRYAO-UHFFFAOYSA-N suberic acid Chemical compound OC(=O)CCCCCCC(O)=O TYFQFVWCELRYAO-UHFFFAOYSA-N 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 238000001029 thermal curing Methods 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical class [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 239000004925 Acrylic resin Substances 0.000 description 1
- 229920000178 Acrylic resin Polymers 0.000 description 1
- 241001631457 Cannula Species 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 229910021591 Copper(I) chloride Inorganic materials 0.000 description 1
- 206010056340 Diabetic ulcer Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241001670157 Gymnura Species 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 1
- SPAGIJMPHSUYSE-UHFFFAOYSA-N Magnesium peroxide Chemical compound [Mg+2].[O-][O-] SPAGIJMPHSUYSE-UHFFFAOYSA-N 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 238000005411 Van der Waals force Methods 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 150000001412 amines Chemical group 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 230000002547 anomalous effect Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 238000000889 atomisation Methods 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000000828 canola oil Substances 0.000 description 1
- 235000019519 canola oil Nutrition 0.000 description 1
- 239000002327 cardiovascular agent Substances 0.000 description 1
- 229940125692 cardiovascular agent Drugs 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- GVPFVAHMJGGAJG-UHFFFAOYSA-L cobalt dichloride Chemical compound [Cl-].[Cl-].[Co+2] GVPFVAHMJGGAJG-UHFFFAOYSA-L 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 150000001924 cycloalkanes Chemical class 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000010894 electron beam technology Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 238000004299 exfoliation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000013023 gasketing Methods 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000013007 heat curing Methods 0.000 description 1
- 239000012943 hotmelt Substances 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- ORTFAQDWJHRMNX-UHFFFAOYSA-N hydroxidooxidocarbon(.) Chemical compound O[C]=O ORTFAQDWJHRMNX-UHFFFAOYSA-N 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000010952 in-situ formation Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 238000000608 laser ablation Methods 0.000 description 1
- 239000012633 leachable Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 229910044991 metal oxide Inorganic materials 0.000 description 1
- 150000004706 metal oxides Chemical group 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 108010004131 poly(beta-D-mannuronate) lyase Proteins 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 239000003361 porogen Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 238000000935 solvent evaporation Methods 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 229920002677 supramolecular polymer Polymers 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 229920000208 temperature-responsive polymer Polymers 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000009772 tissue formation Effects 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 239000002407 tissue scaffold Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000013271 transdermal drug delivery Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
Images
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
- B01J13/02—Making microcapsules or microballoons
- B01J13/06—Making microcapsules or microballoons by phase separation
- B01J13/08—Simple coacervation, i.e. addition of highly hydrophilic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/225—Mixtures of macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/425—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/44—Medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/64—Use of materials characterised by their function or physical properties specially adapted to be resorbable inside the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
- A61L24/0015—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
- A61L24/0036—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
- A61L24/0042—Materials resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/043—Mixtures of macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/18—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/20—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/26—Mixtures of macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/56—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/58—Materials at least partially resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J9/00—Working-up of macromolecular substances to porous or cellular articles or materials; After-treatment thereof
- C08J9/24—Working-up of macromolecular substances to porous or cellular articles or materials; After-treatment thereof by surface fusion and bonding of particles to form voids, e.g. sintering
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09J—ADHESIVES; NON-MECHANICAL ASPECTS OF ADHESIVE PROCESSES IN GENERAL; ADHESIVE PROCESSES NOT PROVIDED FOR ELSEWHERE; USE OF MATERIALS AS ADHESIVES
- C09J123/00—Adhesives based on homopolymers or copolymers of unsaturated aliphatic hydrocarbons having only one carbon-to-carbon double bond; Adhesives based on derivatives of such polymers
- C09J123/02—Adhesives based on homopolymers or copolymers of unsaturated aliphatic hydrocarbons having only one carbon-to-carbon double bond; Adhesives based on derivatives of such polymers not modified by chemical after-treatment
- C09J123/18—Homopolymers or copolymers of hydrocarbons having four or more carbon atoms
- C09J123/20—Homopolymers or copolymers of hydrocarbons having four or more carbon atoms having four to nine carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09J—ADHESIVES; NON-MECHANICAL ASPECTS OF ADHESIVE PROCESSES IN GENERAL; ADHESIVE PROCESSES NOT PROVIDED FOR ELSEWHERE; USE OF MATERIALS AS ADHESIVES
- C09J133/00—Adhesives based on homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides, or nitriles thereof; Adhesives based on derivatives of such polymers
- C09J133/04—Homopolymers or copolymers of esters
- C09J133/06—Homopolymers or copolymers of esters of esters containing only carbon, hydrogen and oxygen, the oxygen atom being present only as part of the carboxyl radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/41—Anti-inflammatory agents, e.g. NSAIDs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Medicinal Chemistry (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Surgery (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Polymers & Plastics (AREA)
- Medicinal Preparation (AREA)
- Processes Of Treating Macromolecular Substances (AREA)
- Adhesive Tapes (AREA)
- Adhesives Or Adhesive Processes (AREA)
- Materials For Medical Uses (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Biological Depolymerization Polymers (AREA)
Description
[0035]硬化した生分解性粒子、足場材料、硬化した生分解性粒子及び足場材料を製造及び使用する方法、並びに硬化した生分解性粒子を含む組成物が提供される。
[0037]本発明の実施形態は、例えば、本明細書に開示される特徴の1つ以上を含まない概念と比較して、金型を使用せずに球状ポリ(オール)-二酸コポリマー粒子を提供し、金型を使用せずに球状PGS粒子を提供し、球状PGS微粒子を提供し、球状PGSナノ粒子を提供し、光開始剤を含まないPGS微粒子を提供し、PGSポリマーから構成されるPGS微粒子を提供し、硬化中にPGSポリマーと反応する化学成分を含まないPGS微粒子を提供し、PGS微粒子から3次元(3-D)足場材料を提供し、薬物装填PGS微粒子を提供し、薬物被覆PGS微粒子を提供し、光開始剤を含まない硬化微粒子を提供し、添加剤を含まない硬化微粒子を提供し、光誘起架橋剤を含まない微粒子を提供し、感圧接着剤の表面化学構造の可視化を可能にし、活性医薬成分(API)の制御放出のための組成物中へのAPIの導入を促進し、又はそれらの組み合わせを提供する。
[0040]本発明は、ポリ(グリセロールセバケート)(PGS)を含む微粒子及び調整された多孔質微粒子ベースの細胞足場材料を製造する方法、かかる方法から形成される粉末複合体を包含するPGS微粒子、PGS微粒子から構成される足場材料を形成する方法、かかる方法から形成されるPGS足場材料、並びに細胞及び薬物送達用途のためのこれらのPGS微粒子及び/又は足場材料の使用に関する。これらのPGS微粒子及び/又は足場材料はまた、細胞培養及び新しい組織の生成のために使用することもできる。
[0043]例示的な実施形態においては、熱硬化性微粒子が金型キャストなしで形成される。微粒子形成技術及びPGS硬化技術の組み合わせによって、個々の微粒子、及び微粒子から形成される3次元足場材料が作製される。
[0051]乳化、相分離、噴霧乾燥/凝結、回転ディスク霧化、ワックス塗布及びホットメルト、並びに凍結乾燥など(しかしながらこれらに限定されない)の微粒子形成技術の異なる方法を利用してPGS微粒子又はコア-シェルPGS微粒子を形成し、その後に連続マトリクス相中で硬化させることができる。
[0056]幾つかの実施形態においては、本方法は、昇温温度において溶融しないニートの架橋された実質的に球形のPGS微粒子(すなわち、添加剤を含まない100%ポリ(グリセロールセバケート))を作製する。
[0060]幾つかの実施形態においては、微粒子の組成物は、約5,000~約50,000Daの範囲の重量平均分子量を有するPGS樹脂を含む。幾つかのかかる実施形態においては、樹脂は約15,000~約25,000Daの範囲の重量平均分子量を有する。
[00109]椎間板又は半月板の修復又は置換のような軟骨用途に関しては、硬質プラスチック様ラクチド及びグリコリドに由来する微粒子は、硬質であり、バルク浸食分解速度を示すという欠点を有する。これらの材料の剛性は、軟骨組織のそれとのコンプライアンス不整合をもたらし、バルク浸食特性は、機械的特性の制御不能な損失及び予測不能な放出速度をもたらす。PGS微粒子は、表面浸食特徴のために水性環境において形状安定性であり、0次放出速度を伴う機械特性の制御された損失をもたらす。したがって、本発明の主な利点は、例えば関節腔及び限定された組織構造において有用なエラストマー性の0次放出微粒子が成長することである。
[00115]幾つかの実施形態においては、3-D-PGS構造体又は足場材料がPGS微粒子から形成される。幾つかの実施形態においては、PGS微粒子を一緒に焼結してマクロPGS構造体/足場材料を形成する。PGS微粒子は、特に微粒子が再造形するために限定された熱可塑性画分を有する場合に、PGS樹脂ベースの接着剤で被覆して焼結を改善することができる。足場材料形成において使用される微粒子は、本明細書に記載される実施形態に従って形成される球状微粒子、不規則な形状の微粒子(PGS粉末粒子を含む)、又はそれらの組み合わせであってよい。
[00131]200mLの重質鉱油を、反応容器内において、マグネチックスターラーバーによる撹拌(400RPM)下で130℃(266°F)に加熱し、真空(10torr)を鉱油に適用して溶解ガスを除去した。真空を除去し、2mLの溶融PGSを、18ゲージ(18G)のニードルを有するシリンジを通して、撹拌下の高温の鉱油に直接ゆっくりと添加した。PGS樹脂を添加した後、10torrの真空を再び適用し、PGS微粒子を130℃(266°F)及び撹拌下に維持して、PGSを硬化させた。20時間後、加熱、真空、及び撹拌を除去した。次いで、硬化したPGS微粒子を洗浄し、回収した。図1は、異なる寸法のスターラーバーから得られる異なる剪断速度を用いて実施例1によって形成された微粒子10及び20を示す(より低い剪断速度はより大きな寸法の微粒子を生じる)。
[00132]200gの重質鉱油を6gのモノラウリンと混合し、反応容器内において、マグネチックスターラーバーによる撹拌(400RPM)下で130℃(266°F)に加熱し、真空(10torr)を鉱油とモノラウリンの混合物に適用して溶解ガスを除去した。真空を除去し、1mLの溶融PGSを、18Gのニードルを有するシリンジを通して、撹拌下の高温の鉱油にゆっくりと添加した。PGS樹脂を添加した後、10torrの真空を再び適用し、PGS微粒子を130℃(266°F)及び撹拌下に維持して、PGSを硬化させた。20時間後、加熱、真空、及び撹拌を除去した。次いで、硬化したPGS微粒子を洗浄し、回収した。図2は、実施例2によって形成された微粒子10を示す。
[00133]乳化剤としてアルギネートで乳化することによってPGS微小球を形成した。99%イソプロピルアルコール中に溶解した50重量%のPGS樹脂を、添加時にアルギネート溶液を撹拌しながら1重量%アルギネートの水溶液に滴下して、未硬化のPGS微小球を形成した。PGS微小球含有アルギネート溶液を90ミリモル(mM)のCaCl2溶液に滴下して、アルギネートを、未硬化のPGS微小球を含む球状体に迅速にイオン性ゲル化した。アルギネートの球状体を脱イオン水で複数回洗浄して、過剰の塩化カルシウムを除去した。次いで、脱イオン水を除去し、水和PGS-アルギネート球状体を残留させた。
[00136]市販のポリイソブチレン(PIB)樹脂と配合したポリ(グリセロール-セバケート)(PGS)樹脂を使用して、PSA配合物のハンドシートを調製した。PSA配合物を、25:75w/w(重量/重量)、50:50w/w、及び75:25w/wのエラストマー(PIB):エステル(PGS)の比で調製した。
[00139]市販の特許品のアクリル系PSA創傷ケア接着剤の試料をPGSと配合して、剥離可能なPSA配合物を形成した。
[00141]PGS熱硬化性樹脂から粉末粒子を作製し、真空オーブン(120℃、10torr)中で24時間硬化させた。熱硬化性樹脂を液体窒素で瞬間凍結し、1cm未満の寸法の小片に粉砕した。次いで、小片を直径500μm未満の微粒子に凍結粉砕した。粉末粒子を一緒に焼結するために、粉末粒子を非常に密に充填し、マイクロ波処理して粒子の再造形を可能にした。
[00143]実施例3に記載のプロセスの変形を用意した。ここでは、剥離のために1重量%クルクミン剤の添加物を溶融したニートのPGS樹脂中に捕捉させ、続いて乳化剤としてアルギネートを使用して微小球に形成する。図13はFTIRスペクトルを示し、これはクルクミン分子構造にのみ存在する1500cm-1付近の芳香族C=Cピークによって、クルクミンがアルギネートからの抽出及びその後の洗浄工程の後にPGS微小球中に存在することを立証している。洗浄後のPGS微小球を図14に示す;観察により呈色された黄色の着色部が示され、これにより、その薬剤を添加せずに形成されたPGS微小球では見られなかったクルクミンの装填が確認された。
[00145]本発明を1つ以上の実施形態を参照して説明したが、本発明の範囲から逸脱することなく、様々な変更を行うことができ、その要素の代わりに均等物を使用することができることが当業者に理解されよう。加えて、その本質的な範囲から逸脱することなく、特定の状況又は材料を本発明の教示に適合させるために多くの修正を行うことができる。したがって、本発明は本発明を実施するために企図されるベストモードとして開示される特定の実施形態に限定されるものではなく、本発明は添付の特許請求の範囲内にあるすべての実施形態を包含することが意図される。更に、詳細な説明において特定される全ての数値は、正確な値及び近似値が両方とも明確に特定されているように解釈されるべきである。
本発明の具体的態様は以下のとおりである。
[1]
複数の硬化微粒子を形成する方法であって、
未硬化状態のポリ(グリセロールセバケート)樹脂を含む組成物を用意する工程;
前記組成物を複数の未硬化微粒子に形成する工程であって、ここで前記複数の未硬化微粒子は光誘起架橋剤を含まない、前記工程;及び、
前記複数の未硬化微粒子を硬化させて前記複数の硬化微粒子を形成する工程;
を含む、前記方法。
[2]
前記組成物を複数の未硬化微粒子に形成する工程が、前記組成物を相-非相溶性液体と混合する工程、及び前記相-非相溶性液体のマトリクス中に前記複数の未硬化微粒子を懸濁させる工程を含む、[1]に記載の方法。
[3]
前記相-非相溶性液体が油である、[2]に記載の方法。
[4]
前記相-非相溶性液体がエラストマーである、[2]に記載の方法。
[5]
前記エラストマーがアクリル系又はイソブチレン系である、[4]に記載の方法。
[6]
前記組成物を複数の未硬化微粒子に形成する工程が、相-非相溶性液体中で前記組成物を剪断混合する工程を含む、[1]に記載の方法。
[7]
前記組成物を複数の未硬化微粒子に形成する工程が、前記組成物を水溶液中に添加して第1のエマルジョンを生成させる工程、及び前記第1のエマルジョンを相-非相溶性液体中に混合して第2のエマルジョンを形成する工程を含む、[1]に記載の方法。
[8]
前記組成物を複数の未硬化微粒子に形成する工程が、前記組成物をアルギネート溶液中に添加してエマルジョンを生成させる工程を含む、[1]に記載の方法。
[9]
前記組成物を複数の未硬化微粒子に形成する工程が、相-非相溶性液体を含む容器中に前記組成物を計量供給する工程を含む、[1]に記載の方法。
[10]
前記組成物を複数の未硬化微粒子に形成する工程が、前記組成物を相-非相溶性液体中に超音波処理する工程を含む、[1]に記載の方法。
[11]
前記複数の未硬化微粒子を硬化させて前記複数の硬化微粒子を形成する工程が、前記複数の未硬化微粒子を伝導加熱する工程を含む、[1]に記載の方法。
[12]
前記複数の未硬化微粒子を硬化させて前記複数の硬化微粒子を形成する工程が、前記複数の未硬化微粒子にマイクロ波放射線を適用する工程を含む、[1]に記載の方法。
[13]
前記ポリ(グリセロールセバケート)樹脂に少なくとも1種類の制御放出薬剤を装填する工程を更に含む、[1]に記載の方法。
[14]
前記複数の硬化微粒子が光開始剤を含まない、[1]に記載の方法。
[15]
前記複数の未硬化微粒子が前記ポリ(グリセロールセバケート)樹脂から構成される、[1]に記載の方法。
[16]
前記ポリ(グリセロールセバケート)樹脂がポリ(グリセロールセバケートアクリレート)樹脂を含む、[1]に記載の方法。
[17]
前記ポリ(グリセロールセバケート)樹脂がポリ(グリセロールセバケートウレタン)樹脂を含む、[1]に記載の方法。
[18]
足場材料を形成する方法であって、
3次元配置のポリ(グリセロールセバケート)を含む複数の微粒子を用意する工程;
前記3次元配置のポリ(グリセロールセバケート)を含む前記複数の微粒子を刺激して前記複数の微粒子を焼結し、それによって複数の細孔を有する前記足場材料を形成する工程;
を含む、前記方法。
[19]
前記3次元配置のポリ(グリセロールセバケート)を含む前記複数の微粒子を刺激して前記複数の微粒子を焼結し、それによって複数の細孔を有する前記足場材料を形成する工程が、マイクロ波放射線を適用する工程を含む、[18]に記載の方法。
[20]
前記3次元配置のポリ(グリセロールセバケート)を含む前記複数の微粒子を刺激して前記複数の微粒子を焼結し、それによって複数の細孔を有する前記足場材料を形成する工程が、対流加熱する工程を含む、[18]に記載の方法。
[21]
前記3次元配置のポリ(グリセロールセバケート)を含む前記複数の微粒子を刺激して前記複数の微粒子を焼結し、それによって複数の細孔を有する前記足場材料を形成する工程が、前記複数の微粒子中の前記ポリ(グリセロールセバケート)の未硬化部分を硬化させる工程を含む、[18]に記載の方法。
[22]
ポリ(グリセロールセバケート)を含む前記複数の微粒子が、複数の微粉化ポリ(グリセロールセバケート)熱硬化性フィラー粒子を含む、[18]に記載の方法。
[23]
ポリ(グリセロールセバケート)を含む前記複数の微粒子が、少なくとも1種類の制御放出薬剤を更に含む、[18]に記載の方法。
[24]
3次元配置のポリ(グリセロールセバケート)熱硬化性樹脂を含む複数の微粒子から形成される足場材料であって、複数の細孔を有する、前記足場材料。
[25]
少なくとも1種類の制御放出薬剤を更に含む、[24]に記載の足場材料。
[26]
ポリ(グリセロールセバケート)を含む前記複数の微粒子が、少なくとも1種類のマイクロ波ドーパントを更に含む、[24]に記載の足場材料。
[27]
前記足場材料が移植可能なバイオリアクターである、[24]に記載の足場材料。
[28]
感圧接着剤を形成する方法であって、
ポリマーエステル樹脂と少なくとも1種類の制御放出薬剤とを混合して、前記少なくとも1種類の制御放出薬剤が装填された前記ポリマーエステル樹脂のエステル相を形成する工程;及び
前記エステル相と、エラストマーポリマー樹脂を含むエラストマー相とを、分散相として複数の微粒子としての前記エステル相、及び連続マトリクスとして前記エラストマー相を与えるように選択されたエステル相:エラストマー相の比で混合して、感圧接着剤組成物を形成する工程;
を含む、前記方法。
[29]
前記ポリマーエステル樹脂がポリ(オール)-二酸コポリマーを含む、[28]に記載の方法。
[30]
前記ポリマーエステル樹脂がポリ(グリセロールセバケート)を含む、[28]に記載の方法。
[31]
前記エラストマーポリマー樹脂がポリイソブチレンを含む、[28]に記載の方法。
[32]
前記複数の微粒子の少なくとも一部を、基材上の前記感圧接着剤組成物の層の自由表面(free surface)に配置する、[27]に記載の方法。
[33]
前記エステル相:エラストマー相の比が、25:75w/w~75:25w/wの範囲である、[28]に記載の方法。
[34]
前記少なくとも1種類の制御放出薬剤が少なくとも1種類の創傷ケア薬剤を含む、[28]に記載の方法。
[35]
前記少なくとも1種類の創傷ケア薬剤が、栄養剤、止血剤、抗生物質、抗菌剤、鎮痛剤、活性医薬成分、軟膏、アルギネート、ヒドロゲル、フィラー、脱臭剤、マヌカハニー、成長促進剤、刺激剤、及びそれらの組み合わせからなる群から選択される、[34]に記載の方法。
[36]
前記感圧接着デバイスを創傷ケアドレッシングに適用する、[35]に記載の方法。
[37]
感圧接着剤組成物であって、
エラストマー性ポリマー樹脂を含む連続マトリクスの第1の相;及び
前記連続マトリクス中の複数の微粒子の第2の相であって、ポリマーエステル樹脂及び少なくとも1種類の制御放出薬剤を含む、前記第2の相;
を含む、前記組成物。
[38]
前記ポリマーエステル樹脂がポリ(オール)-二酸コポリマーを含む、[37]に記載の感圧接着剤組成物。
[39]
前記ポリマーエステル樹脂がポリ(グリセロールセバケート)を含む、[37]に記載の感圧接着剤組成物。
[40]
前記エラストマーポリマー樹脂がポリイソブチレンを含む、[37]に記載の感圧接着剤組成物。
[41]
前記複数の微粒子の少なくとも一部が、基材上の前記感圧接着剤組成物の層の自由表面に配置されている、[37]に記載の感圧接着剤組成物。
[42]
エステル相:エラストマー相の比が、25:75w/w~75:25w/wの範囲である、[37]に記載の感圧接着剤組成物。
[43]
前記少なくとも1種類の制御放出薬剤が少なくとも1種類の創傷ケア薬剤を含む、[37]に記載の感圧接着剤組成物。
[44]
前記少なくとも1種類の創傷ケア薬剤が、栄養剤、止血剤、抗生物質、抗菌剤、鎮痛剤、活性医薬成分、軟膏、アルギネート、ヒドロゲル、フィラー、脱臭剤、マヌカハニー、成長促進剤、刺激剤、及びそれらの組み合わせからなる群から選択される、[37]に記載の感圧接着剤組成物。
Claims (23)
- 複数の硬化微粒子を形成する方法であって、
未硬化状態のポリ(グリセロールセバケート)樹脂を含む組成物を用意する工程;
前記組成物を相-非相溶性液体と混合することにより前記組成物を複数の未硬化微粒子に形成する工程であって、ここで前記複数の未硬化微粒子は光誘起架橋剤を含まない、前記工程;及び、
前記複数の未硬化微粒子を硬化させて前記複数の硬化微粒子を形成する工程;
を含む、前記方法。 - 前記組成物を前記相-非相溶性液体と混合することが、前記相-非相溶性液体のマトリクス中に前記複数の未硬化微粒子を懸濁させる工程を含む、請求項1に記載の方法。
- 前記相-非相溶性液体が油である、請求項1に記載の方法。
- 前記相-非相溶性液体がエラストマーである、請求項1に記載の方法。
- 前記エラストマーがアクリル系又はイソブチレン系である、請求項4に記載の方法。
- 前記組成物を前記相-非相溶性液体と混合することが、前記相-非相溶性液体中で前記組成物を剪断混合する工程を含む、請求項1に記載の方法。
- 前記組成物を前記相-非相溶性液体と混合することが、前記組成物を水溶液中に添加して第1のエマルジョンを生成させる工程、及び前記第1のエマルジョンを前記相-非相溶性液体中に混合して第2のエマルジョンを形成する工程を含む、請求項1に記載の方法。
- 前記相-非相溶性液体がアルギネート溶液であり、前記組成物を前記相-非相溶性液体と混合することが、前記組成物を前記アルギネート溶液中に添加してエマルジョンを生成させる工程を含む、請求項1に記載の方法。
- 前記組成物を前記相-非相溶性液体と混合することが、前記相-非相溶性液体を含む容器中に前記組成物を計量供給する工程を含む、請求項1に記載の方法。
- 前記組成物を前記相-非相溶性液体と混合することが、前記組成物を前記相-非相溶性液体中に超音波処理する工程を含む、請求項1に記載の方法。
- 前記複数の未硬化微粒子を硬化させて前記複数の硬化微粒子を形成する工程が、前記複数の未硬化微粒子を伝導加熱する工程を含む、請求項1に記載の方法。
- 前記複数の未硬化微粒子を硬化させて前記複数の硬化微粒子を形成する工程が、前記複数の未硬化微粒子にマイクロ波放射線を適用する工程を含む、請求項1に記載の方法。
- 前記ポリ(グリセロールセバケート)樹脂に少なくとも1種類の制御放出薬剤を装填する工程を更に含む、請求項1に記載の方法。
- 前記複数の硬化微粒子が光開始剤を含まない、請求項1に記載の方法。
- 前記複数の未硬化微粒子が前記ポリ(グリセロールセバケート)樹脂から構成される、請求項1に記載の方法。
- 前記ポリ(グリセロールセバケート)樹脂がポリ(グリセロールセバケートアクリレート)樹脂を含む、請求項1に記載の方法。
- 前記ポリ(グリセロールセバケート)樹脂がポリ(グリセロールセバケートウレタン)樹脂を含む、請求項1に記載の方法。
- 足場材料を形成する方法であって、
3次元配置のポリ(グリセロールセバケート)を含む複数の硬化微粒子を用意する工程;
前記3次元配置のポリ(グリセロールセバケート)を含む前記複数の硬化微粒子を刺激して前記複数の硬化微粒子を焼結し、それによって複数の細孔を有する前記足場材料を形成する工程;
を含む、前記方法。 - 前記3次元配置のポリ(グリセロールセバケート)を含む前記複数の微粒子を刺激して前記複数の微粒子を焼結し、それによって複数の細孔を有する前記足場材料を形成する工程が、マイクロ波放射線を適用する工程を含む、請求項18に記載の方法。
- 前記3次元配置のポリ(グリセロールセバケート)を含む前記複数の微粒子を刺激して前記複数の微粒子を焼結し、それによって複数の細孔を有する前記足場材料を形成する工程が、対流加熱する工程を含む、請求項18に記載の方法。
- 前記3次元配置のポリ(グリセロールセバケート)を含む前記複数の微粒子を刺激して前記複数の微粒子を焼結し、それによって複数の細孔を有する前記足場材料を形成する工程が、前記複数の硬化微粒子中の前記ポリ(グリセロールセバケート)の未硬化部分を硬化させる工程を含む、請求項18に記載の方法。
- ポリ(グリセロールセバケート)を含む前記複数の硬化微粒子が、複数の微粉化ポリ(グリセロールセバケート)熱硬化性フィラー粒子を含む、請求項18に記載の方法。
- ポリ(グリセロールセバケート)を含む前記複数の硬化微粒子が、少なくとも1種類の制御放出薬剤を更に含む、請求項18に記載の方法。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762479661P | 2017-03-31 | 2017-03-31 | |
US62/479,661 | 2017-03-31 | ||
US201762547559P | 2017-08-18 | 2017-08-18 | |
US62/547,559 | 2017-08-18 | ||
PCT/US2018/025416 WO2018183856A1 (en) | 2017-03-31 | 2018-03-30 | Cured biodegradable microparticles and scaffolds and methods of making and using the same |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2020515690A JP2020515690A (ja) | 2020-05-28 |
JP7216007B2 true JP7216007B2 (ja) | 2023-01-31 |
Family
ID=62025982
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019553806A Active JP7216007B2 (ja) | 2017-03-31 | 2018-03-30 | 硬化した生分解性微粒子及び足場材料、並びにそれらの製造方法及び使用方法 |
Country Status (6)
Country | Link |
---|---|
US (2) | US10556217B2 (ja) |
EP (1) | EP3600465A1 (ja) |
JP (1) | JP7216007B2 (ja) |
CA (1) | CA3057869A1 (ja) |
IL (1) | IL269335B2 (ja) |
WO (1) | WO2018183856A1 (ja) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10918729B2 (en) | 2018-01-31 | 2021-02-16 | The Secant Group, Llc | Osteostimulating elastomeric bone filling compositions |
WO2019165082A1 (en) | 2018-02-21 | 2019-08-29 | The Secant Group, Llc | Dermocosmetic compositions including glycerol-sebacate |
JP2022526975A (ja) | 2019-04-03 | 2022-05-27 | ザ・セカント・グループ・エルエルシー | テキスタイル及び繊維用のヒト細胞によって堆積された細胞外マトリクス被覆 |
TWI820303B (zh) * | 2020-02-20 | 2023-11-01 | 國立清華大學 | 可降解微粒、包含其之可降解產品與應用 |
CN111575097B (zh) * | 2020-06-15 | 2021-04-16 | 清华大学 | 具有光致变粘度的溶液及调控流体粘度的方法 |
JP2023532127A (ja) * | 2020-06-30 | 2023-07-26 | ザ・セカント・グループ・エルエルシー | 多機能重合微小球/微小粒子細胞選別方法およびシステム |
JP2023536456A (ja) | 2020-07-29 | 2023-08-25 | ザ・セカント・グループ・エルエルシー | 架橋ポリ(セバシン酸グリセロール)を含む構造を含む形状誘導型制御放出および保持 |
US20230265249A1 (en) * | 2022-02-24 | 2023-08-24 | The Secant Group, Llc | Urethane-crosslinked polymeric microparticles and processes of manufacturing the same |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016025871A2 (en) | 2014-08-14 | 2016-02-18 | Secant Medical, Inc. | Composition, methods and devices useful for manufacturing of implantable articles |
JP2017516901A (ja) | 2014-05-30 | 2017-06-22 | ザ・セカント・グループ・エルエルシー | ポリマー材料の水媒介製造 |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL6606747A (ja) * | 1965-05-17 | 1966-11-18 | ||
GB1419128A (en) | 1972-01-05 | 1975-12-24 | Koppers Co Inc | Reflex light reflectors |
US4664978A (en) | 1985-03-25 | 1987-05-12 | The Dow Chemical Company | Methods of modifying polymeric surfaces and articles produced thereby |
US4632964A (en) | 1985-03-28 | 1986-12-30 | E. I. Du Pont De Nemours And Company | Flexible finishes from branched aliphatic polyester urethanes and a melamine crosslinker |
US4891409A (en) * | 1986-04-24 | 1990-01-02 | R.J.F. International | Single phase shape-transformable elastomeric compounds |
GB8617831D0 (en) * | 1986-07-22 | 1986-08-28 | British Petroleum Co Plc | Production of porous shaped articles |
US4863974A (en) * | 1988-08-03 | 1989-09-05 | W. L. Gore & Associates, Inc. | Bone growth matrix and process for making it |
EP0578272B1 (en) * | 1988-10-31 | 1997-02-26 | Mitsubishi Denki Kabushiki Kaisha | Porous structural unit |
JPH0347870A (ja) | 1989-07-14 | 1991-02-28 | Kanegafuchi Chem Ind Co Ltd | 樹脂組成物 |
US5401796A (en) | 1993-04-02 | 1995-03-28 | Mitsui Toatsu Chemicals, Inc. | Aliphatic polyester and preparation process thereof |
US6017566A (en) | 1997-10-20 | 2000-01-25 | Wm. Wrigley Jr. Company | Gum base and chewing gum containing edible polyesters and method for manufacture |
IT1307022B1 (it) | 1999-03-15 | 2001-10-23 | Novamont Spa | Processo semplificato per l'ottenimento di poliesteri alifaticibiodegradabili. |
US6444782B1 (en) | 1999-04-26 | 2002-09-03 | Eastman Chemical Company | Process for making pre-gels for a cross-linked branched polyester |
DE10060550C1 (de) * | 2000-12-06 | 2002-04-18 | Lohmann Therapie Syst Lts | Transdermales therapeutisches System mit dem Wirkstoff Oxybutynin und Verfahren zur Herstellung Oxybutynin enthaltender Wirkstoffschichten |
US7722894B2 (en) | 2001-10-22 | 2010-05-25 | Massachusetts Institute Of Technology | Biodegradable polymer |
US20040039440A1 (en) | 2002-07-31 | 2004-02-26 | Elmaleh David R. | Biodegradable sleeves for intravascular devices |
US7341630B1 (en) * | 2003-06-26 | 2008-03-11 | Advanced Cardiovascular Systems, Inc. | Stent coating system |
US7645504B1 (en) | 2003-06-26 | 2010-01-12 | Advanced Cardiovascular Systems, Inc. | Coatings for implantable medical devices comprising hydrophobic and hydrophilic polymers |
US20050148512A1 (en) | 2003-11-10 | 2005-07-07 | Angiotech International Ag | Medical implants and fibrosis-inducing agents |
US20050133046A1 (en) | 2003-12-17 | 2005-06-23 | Becker Timothy A. | Compositions and methods for improved occlusion of vascular defects |
US20060009839A1 (en) | 2004-07-12 | 2006-01-12 | Scimed Life Systems, Inc. | Composite vascular graft including bioactive agent coating and biodegradable sheath |
US20060276875A1 (en) | 2005-05-27 | 2006-12-07 | Stinson Jonathan S | Medical devices |
US7658880B2 (en) | 2005-07-29 | 2010-02-09 | Advanced Cardiovascular Systems, Inc. | Polymeric stent polishing method and apparatus |
KR20080063408A (ko) * | 2005-10-18 | 2008-07-03 | 신벤션 아게 | 열경화성 수지 입자 및 이의 제조 방법 |
US20090011486A1 (en) | 2006-01-12 | 2009-01-08 | Massachusetts Institute Of Technology | Biodegradable Elastomers |
US20070281031A1 (en) * | 2006-06-01 | 2007-12-06 | Guohan Yang | Microparticles and methods for production thereof |
AU2008275009A1 (en) | 2007-07-11 | 2009-01-15 | Georgia Tech Research Corporation | Selectively-releasable adhesives |
US9393137B2 (en) | 2007-09-24 | 2016-07-19 | Boston Scientific Scimed, Inc. | Method for loading a stent into a delivery system |
AU2008326454A1 (en) | 2007-11-19 | 2009-05-28 | Massachusetts Institute Of Technology | Adhesive articles |
WO2009100128A1 (en) * | 2008-02-04 | 2009-08-13 | Massachusetts Institute Of Technology | Particulate delivery vehicles for embryoid bodies |
EP2349363B1 (en) | 2008-10-09 | 2018-12-05 | MiMedx Group, Inc. | Methods of making biocomposite medical constructs and related constructs including artificial tissues, vessels and patches |
US9649404B2 (en) * | 2009-03-05 | 2017-05-16 | Teknimed | Bone filling cement |
US20110038910A1 (en) | 2009-08-11 | 2011-02-17 | Atrium Medical Corporation | Anti-infective antimicrobial-containing biomaterials |
US8716410B2 (en) | 2009-11-13 | 2014-05-06 | Nanyang Technological University | Biodegradable thermoplastic elastomers |
US20110142790A1 (en) | 2009-11-25 | 2011-06-16 | Monash University | Polyol Based - Bioceramic Composites |
US20120064027A1 (en) * | 2010-09-09 | 2012-03-15 | Shalaby Shalaby W | Absorbable adhesive paste |
US20120143347A1 (en) | 2010-12-03 | 2012-06-07 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Elastomeric, Polymeric Bone Engineering and Regeneration Compositions and Methods of Making |
US20120305490A1 (en) * | 2011-06-03 | 2012-12-06 | General Atomics | Oil absorbant polyolefin foam |
US9156241B2 (en) * | 2011-12-12 | 2015-10-13 | Eastman Kodak Company | Laser-imageable flexographic printing precursors and methods of relief imaging |
CA2948171A1 (en) * | 2014-05-08 | 2015-11-12 | Secant Medical, Inc. | Composite lumen with reinforcing textile and matrix |
US9352070B2 (en) | 2014-07-22 | 2016-05-31 | Cormatrix Cardiovascular, Inc. | Tissue prostheses for repairing, reconstructing and replacing damaged or diseased biological structures and associated tissue |
EP3795183A1 (en) * | 2014-08-06 | 2021-03-24 | Poriferous, LLC | Implant with porous outer cortical layer |
WO2016057662A1 (en) | 2014-10-08 | 2016-04-14 | Wake Forest University Health Sciences | Synthesis and use of poly(glycerol-sebacate) films in fibroblast growth regulation |
CN104629023A (zh) | 2014-12-10 | 2015-05-20 | 王美华 | 一种碳纳米管/聚酯复合材料制备方法 |
JP6882312B2 (ja) | 2016-02-25 | 2021-06-02 | ザ・セカント・グループ・エルエルシー | ポリ(グリセロールセバケート)フィラーを含む複合材料 |
CA3033989A1 (en) | 2016-08-18 | 2018-02-22 | The Secant Group, Llc | Composition, articles and methods for wound care |
EP3630135A4 (en) | 2017-05-29 | 2021-03-03 | Orgenesis Ltd. | COMPOSITIONS AND METHOD OF PROVIDING CELL REPLACEMENT THERAPY |
-
2018
- 2018-03-30 JP JP2019553806A patent/JP7216007B2/ja active Active
- 2018-03-30 WO PCT/US2018/025416 patent/WO2018183856A1/en active Application Filing
- 2018-03-30 CA CA3057869A patent/CA3057869A1/en not_active Abandoned
- 2018-03-30 US US15/941,745 patent/US10556217B2/en active Active
- 2018-03-30 EP EP18719005.3A patent/EP3600465A1/en active Pending
-
2019
- 2019-09-13 IL IL269335A patent/IL269335B2/en unknown
-
2020
- 2020-01-06 US US16/735,251 patent/US11602721B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2017516901A (ja) | 2014-05-30 | 2017-06-22 | ザ・セカント・グループ・エルエルシー | ポリマー材料の水媒介製造 |
WO2016025871A2 (en) | 2014-08-14 | 2016-02-18 | Secant Medical, Inc. | Composition, methods and devices useful for manufacturing of implantable articles |
US20160046832A1 (en) | 2014-08-14 | 2016-02-18 | Secant Medical, Inc. | Composition, methods and devices useful for manufacturing of implantable articles |
Also Published As
Publication number | Publication date |
---|---|
WO2018183856A1 (en) | 2018-10-04 |
JP2020515690A (ja) | 2020-05-28 |
US20200139330A1 (en) | 2020-05-07 |
IL269335B1 (en) | 2023-04-01 |
CA3057869A1 (en) | 2018-10-04 |
IL269335B2 (en) | 2023-08-01 |
US20180280912A1 (en) | 2018-10-04 |
US10556217B2 (en) | 2020-02-11 |
US11602721B2 (en) | 2023-03-14 |
IL269335A (en) | 2019-11-28 |
EP3600465A1 (en) | 2020-02-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7216007B2 (ja) | 硬化した生分解性微粒子及び足場材料、並びにそれらの製造方法及び使用方法 | |
Patil et al. | A review on ionotropic gelation method: novel approach for controlled gastroretentive gelispheres | |
Mi et al. | Chitin/PLGA blend microspheres as a biodegradable drug delivery system: a new delivery system for protein | |
EP0981373B2 (en) | Biofunctional polymers prepared in supercritical fluid | |
JP2016005555A (ja) | 成型可能な骨代用材の生成 | |
Das et al. | Recent advances in hydrogels for biomedical applications | |
Piras et al. | Self-assembled low-molecular-weight gelator injectable microgel beads for delivery of bioactive agents | |
Lin et al. | 5-Fluorouracil encapsulated HA/PLGA composite microspheres for cancer therapy | |
Aydin | Effect of temperature on drug release: Production of 5‐FU‐encapsulated hydroxyapatite‐gelatin polymer composites via spray drying and analysis of in vitro kinetics | |
Girones Molera et al. | Bioresorbable and nonresorbable polymers for bone tissue engineering Jordi Girones | |
US20230172859A1 (en) | Drug-loaded microbead compositions, embolization compositions and associated methods | |
KR20160033897A (ko) | 조직 수복용 조성물 및 이의 제조방법 | |
JPH04217914A (ja) | 徐放性製剤の製造方法 | |
US11801222B2 (en) | Manufacturing method for granule | |
Kumari et al. | Mucoadhesive microspheres: A review | |
Manna et al. | Interpenetrating polymer network in microparticulate systems: drug delivery and biomedical application | |
Chamradová et al. | The effect of hydroxyapatite particle size on viscoelastic properties and calcium release from a thermosensitive triblock copolymer | |
Carrêlo et al. | Injectable Composite Systems Based on Microparticles in Hydrogels for Bioactive Cargo Controlled Delivery. Gels 2021, 7, 147 | |
Çimen et al. | Injectable Functional Polymeric Cryogels for Biological Applications | |
Reyes-Ortega et al. | Smart Polymeric-Based Microencapsulation: A Promising Synergic Combination | |
KR20180116162A (ko) | 유무기 복합 과립 및 이의 제조방법 | |
Joshi et al. | 1Department of Pharmaceutical Sciences, Mohanlal Sukhadia University, Udaipur, India, 2Smriti College of Pharmaceutical Education, Indore, India, 3Shobhaben Pratapbhai Patel School of Pharmacy & Technology Management, SVKM’s NMIMS (Deemed to be University), Mumbai, India | |
CN115463115A (zh) | 精准药物释放和安全给药的载药薄膜及其制备和应用 | |
Yoanidu et al. | Recent applications of polymer materials in biomedical sciences | |
CHAMRADOVÁ et al. | POLYMERIC MATERIALS FOR THE CONTROLLED DRUG DELIVERY AND CONTROLLED RELEASE OF ACTIVE SUBSTANCES |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210210 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20220117 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220225 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220524 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20220524 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220913 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221206 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230104 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230119 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7216007 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |